## Cryptococcosis

Infectious Disease Clinics of North America 16, 837-874 DOI: 10.1016/s0891-5520(02)00036-3

**Citation Report** 

#	Article	IF	CITATIONS
2	Progress in functional genomics approaches to antifungal drug target discovery. Trends in Microbiology, 2003, 11, 470-478.	3.5	28
3	â€~Ready made' virulence and â€~dual use' virulence factors in pathogenic environmental fungi — the Cryptococcus neoformans paradigm. Current Opinion in Microbiology, 2003, 6, 332-337.	2.3	187
4	Fungal Cell Wall Septation and Cytokinesis Are Inhibited by Bleomycins. Antimicrobial Agents and Chemotherapy, 2003, 47, 3281-3289.	1.4	17
5	Molecular Analysis of Cryptococcus neoformans Mitochondrial Cytochrome b Gene Sequences. Journal of Clinical Microbiology, 2003, 41, 5572-5576.	1.8	26
6	Cryptococcus neoformans Gene Expression during Experimental Cryptococcal Meningitis. Eukaryotic Cell, 2003, 2, 1336-1349.	3.4	129
7	The art of serendipity: killing of Caenorhabditis elegans by human pathogens as a model of bacterial and fungal pathogenesis. Expert Review of Anti-Infective Therapy, 2003, 1, 167-173.	2.0	37
8	Phenotypic Switching and βâ€ <i>N</i> â€Acetylhexosaminidase Activity of the Pathogenic Yeast <i>Trichosporon asahii</i> . Microbiology and Immunology, 2004, 48, 237-242.	0.7	24
9	Involvement of CD14, Toll-Like Receptors 2 and 4, and MyD88 in the Host Response to the Fungal Pathogen Cryptococcus neoformans In Vivo. Infection and Immunity, 2004, 72, 5373-5382.	1.0	173
10	Immunoreactivity of Cryptococcal Antigen Is Not Stable under Prolonged Incubations in Human Serum. Journal of Clinical Microbiology, 2004, 42, 2786-2788.	1.8	12
11	Evaluation of the NCCLS M44-P Disk Diffusion Method for Determining Susceptibilities of 276 Clinical Isolates of Cryptococcus neoformans to Fluconazole. Journal of Clinical Microbiology, 2004, 42, 380-383.	1.8	27
12	CNLAC1 Is Required for Extrapulmonary Dissemination of Cryptococcus neoformans but Not Pulmonary Persistence. Infection and Immunity, 2004, 72, 1693-1699.	1.0	108
13	Unexpected Diversity in the Fine Specificity of Monoclonal Antibodies That Use the Same V Region Gene to Glucuronoxylomannan of <i>Cryptococcus neoformans</i> . Journal of Immunology, 2004, 172, 3670-3677.	0.4	24
14	Immunogenicity and Efficacy of Cryptococcus neoformans Capsular Polysaccharide Glucuronoxylomannan Peptide Mimotope-Protein Conjugates in Human Immunoglobulin Transgenic Mice. Infection and Immunity, 2004, 72, 196-208.	1.0	59
15	A synthetic peptide as a novel anticryptococcal agent. Cellular Microbiology, 2004, 6, 953-961.	1.1	45
16	Cryptococcus neoformans Kin1 protein kinase homologue, identified through a Caenorhabditis elegans screen, promotes virulence in mammals. Molecular Microbiology, 2004, 54, 407-419.	1.2	81
17	Fungal infections of the central nervous system. Seminars in Roentgenology, 2004, 39, 505-518.	0.2	3
18	Investigation of the basis of virulence in serotype A strains of Cryptococcus neoformans from apparently immunocompetent individuals. Current Genetics, 2004, 46, 92-102.	0.8	28
19	Cryptococcus neoformans mitochondrial genomes from serotype A and D strains do not influence virulence. Current Genetics, 2004, 46, 193-204.	0.8	47

#	Article	IF	CITATIONS
20	Effects of Voriconazole on Cryptococcus neoformans. Antimicrobial Agents and Chemotherapy, 2004, 48, 2014-2020.	1.4	71
21	Emerging fungal diseases: the importance of the host. Clinics in Laboratory Medicine, 2004, 24, 691-719.	0.7	31
23	Enlarging Parietal Mass with Lytic Skull Lesion. Pediatric Infectious Disease Journal, 2004, 23, 589.	1.1	9
25	The Nramp orthologue of Cryptococcus neoformans is a pH-dependent transporter of manganese, iron, cobalt and nickel. Biochemical Journal, 2005, 385, 225-232.	1.7	34
26	Prevention of cryptococcosis in HIV-infected patients with limited access to highly active antiretroviral therapy: evidence for primary azole prophylaxis. HIV Medicine, 2005, 6, 253-259.	1.0	5
27	Mucocutaneous Manifestation of Cryptococcal Infection: Report of a Case and Review of the Literature. Journal of Oral and Maxillofacial Surgery, 2005, 63, 1543-1549.	0.5	24
28	B cell response during infection with the MAT a and MAT alpha mating types of Cryptococcus neoformans. Microbes and Infection, 2005, 7, 118-125.	1.0	4
29	Cryptococcus neoformans: A sugar-coated killer with designer genes. FEMS Immunology and Medical Microbiology, 2005, 45, 395-404.	2.7	92
30	Simultaneous chronic pulmonary paracoccidiodomycosis and disseminated cryptococcosis in a non-HIV patient. Mycopathologia, 2005, 159, 373-376.	1.3	3
31	Innate and Acquired Immunity in Cryptococcus neoformans Infections of the Central Nervous System. , 2005, , 459-488.		0
33	Cryptococcal Small-Bowel Obstruction in an Hiv-Positive Patient. Journal of the Royal Society of Medicine, 2005, 98, 513-514.	1.1	4
34	The Cellular Responses Induced by the Capsular Polysaccharide of Cryptococcus neoformans Differ Depending on the Presence or Absence of Specific Protective Antibodies. Current Molecular Medicine, 2005, 5, 413-420.	0.6	28
35	Protective Antifungal Yeast Killer Toxin-Like Antibodies. Current Molecular Medicine, 2005, 5, 443-452.	0.6	33
36	Phenotypic Switching of Cryptococcus neoformans Can Produce Variants That Elicit Increased Intracranial Pressure in a Rat Model of Cryptococcal Meningoencephalitis. Infection and Immunity, 2005, 73, 1779-1787.	1.0	49
37	Dual Infections with Pigmented and Albino Strains of Cryptococcus neoformans in Patients with or without Human Immunodeficiency Virus Infection in India. Journal of Clinical Microbiology, 2005, 43, 4766-4772.	1.8	27
38	Cryptococcal Antigen Test Revisited: Significance for Cryptococcal Meningitis Therapy Monitoring in a Tertiary Chinese Hospital. Journal of Clinical Microbiology, 2005, 43, 2989-2990.	1.8	51
39	Cryptococcus neoformans Gene Involved in Mammalian Pathogenesis Identified by a Caenorhabditis elegans Progeny-Based Approach. Infection and Immunity, 2005, 73, 8219-8225.	1.0	63
40	Opsonic Requirements for Dendritic Cell-Mediated Responses to Cryptococcus neoformans. Infection and Immunity, 2005, 73, 592-598.	1.0	74

#	Article	IF	CITATIONS
41	Cryptococcal small-bowel obstruction in an HIV-positive patient. Journal of the Royal Society of Medicine, 2005, 98, 513-514.	1.1	8
42	Liposomal amphotericin B: clinical experience and perspectives. Expert Review of Anti-Infective Therapy, 2005, 3, 167-181.	2.0	49
43	Non-Aspergillus Fungal Pneumonia in Transplant Recipients. Clinics in Chest Medicine, 2005, 26, 675-690.	0.8	13
44	The prognosis of hearing impairment complicating HIV-negative cryptococcal meningitis. Neurology, 2005, 65, 320-322.	1.5	17
45	Prospects of vaccines for medically important fungi Feasibility and prospects for a vaccine to prevent cryptococcosis. Medical Mycology, 2005, 43, 667-680.	0.3	31
46	Galleria mellonella as a Model System To Study Cryptococcus neoformans Pathogenesis. Infection and Immunity, 2005, 73, 3842-3850.	1.0	421
47	Emergence of Amphotericin B-ResistantCryptococcus laurentiiMeningoencephalitis Shortly After Treatment forCryptococcus neoformansMeningitis in a Patient with AIDS. AIDS Patient Care and STDs, 2006, 20, 227-232.	1.1	31
49	Infecciones por hongos levaduriformes: Candida sp. y Cryptococcus sp Medicine, 2006, 9, 3693-3701.	0.0	1
50	Cryptococcosis. Infectious Disease Clinics of North America, 2006, 20, 507-544.	1.9	354
52	Identification of novel cell-wall active antifungal compounds. International Journal of Antimicrobial Agents, 2006, 28, 361-365.	1.1	6
53	The Poor Prognosis of Central Nervous System Cryptococcosis among Nonimmunosuppressed Patients: A Call for Better Disease Recognition and Evaluation of Adjuncts to Antifungal Therapy. Clinical Infectious Diseases, 2006, 42, 1443-1447.	2.9	112
54	Phospholipase A2 and Phospholipase B activities in fungi. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2006, 1761, 1391-1399.	1.2	85
55	Criptococose pulmonar isolada em paciente imunocompetente. Jornal Brasileiro De Pneumologia, 2006, 32, 476-480.	0.4	10
57	Necrotising cryptococcal vasculitis in an HIV-negative woman. Mycoses, 2006, 49, 152-154.	1.8	10
58	Cryptococcus neoformans capsular polysaccharide component galactoxylomannan induces apoptosis of human T-cells through activation of caspase-8. Cellular Microbiology, 2006, 8, 267-275.	1.1	68
59	Phenotypic switching and its implications for the pathogenesis ofCryptococcus neoformans. FEMS Yeast Research, 2006, 6, 480-488.	1.1	34
60	The Skn7 response regulator ofCryptococcus neoformansis involved in oxidative stress signalling and augments intracellular survival in endothelium. FEMS Yeast Research, 2006, 6, 652-661.	1.1	40
61	Lipid metabolism inCryptococcus neoformans. FEMS Yeast Research, 2006, 6, 469-479.	1.1	17

#	Article	IF	Citations
62	Glucuronoxylomannan-mediated interaction of Cryptococcus neoformans with human alveolar cells results in fungal internalization and host cell damage. Microbes and Infection, 2006, 8, 493-502.	1.0	58
63	Immune Response and Immunotherapy to Cryptococcus Infections. Immunologic Research, 2006, 35, 191-208.	1.3	17
64	Fungal Thyroiditis: An Overview. Mycopathologia, 2006, 161, 129-139.	1.3	50
65	Efficacy of voriconazole in experimental Cryptococcus neoformans infection. Mycopathologia, 2006, 162, 111-114.	1.3	13
66	How to diagnose and treat fungal infections in chronic prostatitis. Current Urology Reports, 2006, 7, 320-328.	1.0	52
67	Microbial translocation of the blood–brain barrier. International Journal for Parasitology, 2006, 36, 607-614.	1.3	83
68	Identification and comparative analysis of sixteen fungal peptidyl-prolyl cis/trans isomerase repertoires. BMC Genomics, 2006, 7, 244.	1.2	41
69	Immunotherapy for Fungal Infections. Clinical Infectious Diseases, 2006, 42, 507-515.	2.9	91
70	Evidence of mRNA-Mediated Intron Loss in the Human-Pathogenic Fungus Cryptococcus neoformans. Eukaryotic Cell, 2006, 5, 789-793.	3.4	55
71	Phenotypic switching in Cryptococcus neoformans. Microbiology (United Kingdom), 2006, 152, 3-9.	0.7	39
72	Characterization and Regulation of the Trehalose Synthesis Pathway and Its Importance in the Pathogenicity of Cryptococcus neoformans. Infection and Immunity, 2006, 74, 5877-5887.	1.0	144
73	Cryptococcal parotid involvement: an uncommon localization ofCryptococcus neoformans. Medical Mycology, 2006, 44, 279-283.	0.3	16
74	The Physical Properties of the Capsular Polysaccharides from Cryptococcus neoformans Suggest Features for Capsule Construction. Journal of Biological Chemistry, 2006, 281, 1868-1875.	1.6	124
75	Phenotypic Switching in a Cryptococcus neoformans Variety gattii Strain Is Associated with Changes in Virulence and Promotes Dissemination to the Central Nervous System. Infection and Immunity, 2006, 74, 896-903.	1.0	48
76	Identification and Characterization of CPS1 as a Hyaluronic Acid Synthase Contributing to the Pathogenesis of Cryptococcus neoformans Infection. Eukaryotic Cell, 2007, 6, 1486-1496.	3.4	88
77	Study of common functional genetic polymorphisms of <i>FCGR2A</i> , <i>3A</i> and <i>3B</i> genes and the risk for cryptococcosis in HIV-uninfected patients. Medical Mycology, 2007, 45, 513-518.	0.3	34
78	Self-Aggregation of Cryptococcus neoformans Capsular Glucuronoxylomannan Is Dependent on Divalent Cations. Eukaryotic Cell, 2007, 6, 1400-1410.	3.4	135
79	Dependence of Macrophage Phagocytic Efficacy on Antibody Concentration. Infection and Immunity, 2007, 75, 1904-1915.	1.0	30

#	ARTICLE CEREBELLAR CRYPTOCOCCOMA IN A PATIENT WITH UNDIAGNOSED SARCOIDOSIS. Neurosurgery, 2007, 60,	IF	Citations
80	ES71-E571.	0.6	20
81	MAP kinase pathways as regulators of fungal virulence. Trends in Microbiology, 2007, 15, 181-190.	3.5	145
82	Antibodies. , 2007, , 235-256.		0
83	Cryptococcus neoformans laccase catalyses melanin synthesis from both d- and l-DOPA. Microbiology (United Kingdom), 2007, 153, 3954-3962.	0.7	123
84	The Temperature-Sensitive Role of Cryptococcus neoformans ROM2 in Cell Morphogenesis. PLoS ONE, 2007, 2, e368.	1.1	18
85	Molecular diversity of serial Cryptococcus neoformans isolates from AIDS patients in the city of São Paulo, Brazil. Memorias Do Instituto Oswaldo Cruz, 2007, 102, 777-784.	0.8	14
86	Estudio clÃnico y epidemiológico de la criptococosis en Colombia: resultados de nueve años de la encuesta nacional, 1997-2005. Biomedica, 2007, 27, 94.	0.3	49
87	Invasive Cryptococcus neoformans infection in an asplenic patient. Journal of Infection, 2007, 55, 566-568.	1.7	15
88	Invasive fungal infections and antifungal therapies in solid organ transplant recipients. Transplant International, 2007, 20, 993-1015.	0.8	58
89	Cryptococcosis in liver and kidney transplant recipients receiving anti-thymocyte globulin or alemtuzumab. Transplant Infectious Disease, 2007, 9, 22-27.	0.7	77
90	Gomesin, a peptide produced by the spiderAcanthoscurria gomesiana, is a potent anticryptococcal agent that acts in synergism with fluconazole. FEMS Microbiology Letters, 2007, 274, 279-286.	0.7	47
91	How to diagnose and treat fungal infections in chronic prostatitis. Current Fungal Infection Reports, 2007, 1, 33-41.	0.9	1
92	MALDI-TOF mass signatures for differentiation of yeast species, strain grouping and monitoring of morphogenesis markers. Analytical and Bioanalytical Chemistry, 2008, 392, 439-449.	1.9	103
93	Aspergillus to Zygomycetes: Causes, Risk Factors, Prevention, and Treatment of Invasive Fungal Infections. Infection, 2008, 36, 296-313.	2.3	95
94	Mechanisms of microbial traversal of the blood–brain barrier. Nature Reviews Microbiology, 2008, 6, 625-634.	13.6	361
95	Pulmonary cryptococcosis: Clinical, radiographical and serological markers of dissemination. Respirology, 2008, 13, 247-251.	1.3	28
96	Systemic lupus erythematosusâ€associated cutaneous cryptococcosis treated successfully with an intermittent 3â€day on/off cycle of itraconazole. Journal of Dermatology, 2008, 35, 778-781.	0.6	3
97	Evaluación del método de difusión en agar Neo-Sensitabs® para la determinación de la sensibilidad a los antifúngicos de Cryptococcus gattii, utilizando tres medios de cultivo diferentes. Revista Iberoamericana De Micologia, 2008, 25, 215-220.	0.4	4

#	Article	IF	CITATIONS
98	Cryptococcus neoformans induces IL-8 secretion and CXCL1 expression by human bronchial epithelial cells. Respiratory Research, 2008, 9, 9.	1.4	38
99	CO2 Sensing and Virulence of Candida albicans. , 2008, , 83-94.		4
100	Hyphal Growth and Virulence in Candida albicans. , 2008, , 95-114.		1
102	Pericardial effusion due to Cryptococcus neoformans in a patient with cystic fibrosis following lung transplantation. International Journal of Infectious Diseases, 2008, 12, 452.	1.5	10
103	Extracellular Vesicles Produced by <i>Cryptococcus neoformans</i> Contain Protein Components Associated with Virulence. Eukaryotic Cell, 2008, 7, 58-67.	3.4	491
104	Therapeutic Efficacy of a Conjugate Vaccine Containing a Peptide Mimotope of Cryptococcal Capsular Polysaccharide Glucuronoxylomannan. Vaccine Journal, 2008, 15, 1176-1187.	3.2	40
105	IFN-α/β Signaling Is Required for Polarization of Cytokine Responses toward a Protective Type 1 Pattern during Experimental Cryptococcosis. Journal of Immunology, 2008, 181, 566-573.	0.4	52
107	Phenotypic Switching in <i>Cryptococcus neoformans</i> Contributes to Virulence by Changing the Immunological Host Response. Infection and Immunity, 2008, 76, 4322-4331.	1.0	24
108	<i>Case Report:</i> Cryptococcal Meningitis Manifesting as a Large Abdominal Cyst in a HIV-Infected Patient with a CD4 Count Greater than 400 cells/mm <sup>3</sup> . AIDS Patient Care and STDs, 2008, 22, 359-363.	1.1	5
109	Sophisticated Functions for a Simple Molecule: The Role of Glucosylceramides in Fungal Cells. Lipid Insights, 2008, 2, LPI.S1014.	1.0	4
110	Cryptococcal Lymphadenitis as a Manifestation of Immune Reconstitution Inflammatory Syndrome in an HIV-Positive Patient: A Case Report and Review of the Literature. International Journal of Immunopathology and Pharmacology, 2008, 21, 751-756.	1.0	15
111	CapÃŧulo 3: criptococose pulmonar. Jornal Brasileiro De Pneumologia, 2009, 35, 1136-1144.	0.4	19
112	First isolation of Cryptococcus gattii molecular type VGII and Cryptococcus neoformans molecular type VNI from environmental sources in the city of Belém, Pará, Brazil. Memorias Do Instituto Oswaldo Cruz, 2009, 104, 662-664.	0.8	27
113	Clinical Presentation, Diagnosis and Management of <i>Cryptococcus gattii</i> Cases: Lessons Learned from British Columbia. Canadian Journal of Infectious Diseases and Medical Microbiology, 2009, 20, 23-28.	0.7	57
114	Histopathology, serology and cultures in the diagnosis of cryptococcosis. Revista Do Instituto De Medicina Tropical De Sao Paulo, 2009, 51, 255-259.	0.5	42
115	The epidemiology of fungal infections. , 2009, , 1-14.		5
116	The still obscure attributes of cryptococcal glucuronoxylomannan. Medical Mycology, 2009, 47, 783-788.	0.3	20
117	Evolutionarily conserved recognition and innate immunity to fungal pathogens by the scavenger receptors SCARF1 and CD36. Journal of Experimental Medicine, 2009, 206, 637-653.	4.2	228

#	Article	IF	CITATIONS
118	Acute renal failure presenting as a granulomatous interstitial nephritis due to cryptococcal infection. Kidney International, 2009, 76, 453-458.	2.6	11
119	Involvement of Glycoreceptors in Galactoxylomannan-Induced T Cell Death. Journal of Immunology, 2009, 182, 6003-6010.	0.4	20
120	Immune Restoration Diseases Reflect Diverse Immunopathological Mechanisms. Clinical Microbiology Reviews, 2009, 22, 651-663.	5.7	57
121	Multimodal treatment of recurrent sinonasal cryptococcal granulomas in a horse. Journal of the American Veterinary Medical Association, 2009, 235, 723-730.	0.2	23
122	Evaluation of three commercial latex agglutination kits and a commercial enzyme immunoassay for the detection of cryptococcal antigen. Medical Mycology, 2009, 47, 336-338.	0.3	30
123	<i>Cryptococcus gattii</i> : An Emerging Cause of Fungal Disease in North America. Interdisciplinary Perspectives on Infectious Diseases, 2009, 2009, 1-13.	0.6	68
124	<i>Cryptococcus gattii</i> : Emergence in Western North America: Exploitation of a Novel Ecological Niche. Interdisciplinary Perspectives on Infectious Diseases, 2009, 2009, 1-8.	0.6	47
125	The role of the cell wall in fungal pathogenesis. Microbial Biotechnology, 2009, 2, 308-320.	2.0	60
126	Pathogen translocation across the blood-brain barrier. FEMS Immunology and Medical Microbiology, 2009, 57, 203-213.	2.7	46
127	Unusual presentations of nervous system infection by Cryptococcus neoformans. Clinical Neurology and Neurosurgery, 2009, 111, 638-642.	0.6	22
128	The common Cryptococcus neoformans glucuronoxylomannan M2 motif elicits non-protective antibodies. Vaccine, 2009, 27, 3513-3518.	1.7	35
129	Fungal infections of the respiratory tract. , 2009, , 561-589.		Ο
130	Loss of Allergen 1 Confers a Hypervirulent Phenotype That Resembles Mucoid Switch Variants of <i>Cryptococcus neoformans</i> . Infection and Immunity, 2009, 77, 128-140.	1.0	24
131	Cryptococcosis of the Upper Genital Tract. AIDS Patient Care and STDs, 2009, 23, 71-73.	1.1	5
132	Cryptococcal Epidural Abscess With Bone Involvement. Infectious Diseases in Clinical Practice, 2009, 17, 193-195.	0.1	2
133	Cryptococcal Choroid Plexitis an Uncommon Fungal Disease. Case Report and Review. Canadian Journal of Neurological Sciences, 2009, 36, 117-122.	0.3	11
134	Cryptococcosis and tuberculosis co-infection at a university hospital in Taiwan, 1993–2006. Infection, 2010, 38, 373-379.	2.3	23
135	Outcomes of central nervous system cryptococcosis vary with host immune function: Results from a multi-center, prospective study. Journal of Infection, 2010, 61, 419-426.	1.7	41

ARTICLE IF CITATIONS # Infections of the Nervous System., 2010, , 483-518. 0 136 Epidemiology of<i>Cryptococcus gattii</i>, British Columbia, Canada, 1999–2007. Emerging Infectious 230 Diseases, 2010, 16, 251-257. 138 Mycoses and algal infections., 2010, , 581-606.e24. 8 Cryptococcus neoformans Overcomes Stress of Azole Drugs by Formation of Disomy in Specific 380 Multiple Chromosomes. PLoS Pathogens, 2010, 6, e1000848. Pulmonary Cryptococcosis with Severe Eosinophilia in an Immunocompetent Patient. Journal of 140 0.7 5 Chemotherapy, 2010, 22, 366-367. Galactoxylomannans from Cryptococcus neoformans Varieties <i>neoformans</i> and <i>grubii</i> Are Structurally and Antigenically Variable. Eukaryotic Cell, 2010, 9, 1018-1028. 3.4 Heteroresistance of <i>Cryptococcus gattii</i> to Fluconazole. Antimicrobial Agents and 142 1.4 87 Chemotherapy, 2010, 54, 2303-2311. Cryptococcosis in systemic lupus erythematosus: a series of six cases. Lupus, 2010, 19, 639-645. 143 0.8 21 Cryptococcal Cell Morphology Affects Host Cell Interactions and Pathogenicity. PLoS Pathogens, 144 2.1 291 2010, 6, e1000953. Immunomodulatory Effects of Serotype B Glucuronoxylomannan from <i>Cryptococcus gattii</i> 145 1.0 Correlate with Polysaccharide Diameter. Infection and Immunity, 2010, 78, 3861-3870. Dueling in the lung: how Cryptococcus spores race the host for survival. Current Opinion in 146 2.371 Microbiology, 2010, 13, 437-442. Colitis as a manifestation of infliximab-associated disseminated cryptococcosis. International Journal 148 1.5 30 of Infectious Diseases, 2010, 14, e436-e440. Disseminated cryptococcosis resulting in miscarriage in a woman without other immunocompromise: 149 1.5 5 a case report. International Journal of Infectious Diseases, 2010, 14, e441-e443. Histoplasmosis, Blastomycosis, Coccidioidomycosis, and Cryptococcosis., 2011, , 573-581. A Survey of the <i>In Vitro</i> Antifungal Activity of Heather (<i>Erica</i> Sp.) Organic Honey. Journal 152 0.8 45 of Medicinal Food, 2011, 14, 1284-1288. Carbohydrates and Immunology: Synthetic Oligosaccharide Antigens for Vaccine Formulation. European Journal of Organic Chemistry, 2011, 2011, 5723-5777. 133 Cryptococcal Meningitis in Patients with or without Human Immunodeficiency Virus: Experience in a 154 0.9 35 Tertiary Hospital. Yonsei Medical Journal, 2011, 52, 482. Cryptococcuria as manifestation of disseminated cryptococcosis: Staib agar as a selective 1.8 identification medium. Mycoses, 2011, 54, e760-e766.

#	Article	IF	CITATIONS
156	Eosinophils elicit proliferation of naive and fungal-specific cells in vivo so enhancing a T helper type 1 cytokine profile in favour of a protective immune response against Cryptococcus neoformans infection. Immunology, 2011, 134, 198-213.	2.0	18
157	Effects of microplusin, a copper-chelating antimicrobial peptide, against Cryptococcus neoformans. FEMS Microbiology Letters, 2011, 324, 64-72.	0.7	30
158	Cryptococcus neoformanssuppresses the activation of bone marrow–derived dendritic cells stimulated with its own DNA, but not with DNA from other fungi. FEMS Immunology and Medical Microbiology, 2011, 63, 363-372.	2.7	8
159	Extrahepatic biliary cryptococcosis: A case report. Journal of Digestive Diseases, 2011, 12, 500-504.	0.7	2
160	First Environmental Isolations of Cryptococcus neoformans and Cryptococcus gattii in Tunisia and Review of Published Studies on Environmental Isolations in Africa. Mycopathologia, 2011, 171, 355-360.	1.3	37
161	Antifungal effect of lavender honey against Candida albicans, Candida krusei and Cryptococcus neoformans. Journal of Food Science and Technology, 2011, 48, 640-643.	1.4	55
162	Genome-wide expression profiling of the response to short-term exposure to fluconazole in Cryptococcus neoformans serotype A. BMC Microbiology, 2011, 11, 97.	1.3	43
163	<i>Cryptococcus neoformans</i> galactoxylomannan is a potent negative immunomodulator, inspiring new approaches in anti-inflammatory immunotherapy. Immunotherapy, 2011, 3, 997-1005.	1.0	39
164	Symptomatic duodenal cryptococcosis in HIV-infected individuals. Medical Mycology, 2011, 49, 1-4.	0.3	3
165	Pulmonary Cryptococcus Infection After Mono-Chemotherapy With Gemcitabine. Respiratory Care, 2011, 56, 339-341.	0.8	5
166	Cryptococcus neoformans Requires a Functional Glycolytic Pathway for Disease but Not Persistence in the Host. MBio, 2011, 2, e00103-11.	1.8	89
167	Regulatory Circuitry Governing Fungal Development, Drug Resistance, and Disease. Microbiology and Molecular Biology Reviews, 2011, 75, 213-267.	2.9	448
168	The role of azoles in the treatment of invasive mycoses: review of the Infectious Diseases Society of America guidelines. Current Opinion in Infectious Diseases, 2011, 24, S1-S13.	1.3	11
169	Central Nervous System Cryptococcosis among a Cohort of HIV Infected Patients from a University Hospital of North India. Journal of Clinical and Diagnostic Research JCDR, 2012, 6, 1385-7.	0.8	4
171	Primary pulmonary cryptococcosis: evaluation of CT characteristics in 26 immunocompetent Chinese patients. Acta Radiologica, 2012, 53, 668-674.	0.5	17
172	Genetic Diversity and Genomic Plasticity of <i>Cryptococcus neoformans</i> AD Hybrid Strains. G3: Genes, Genomes, Genetics, 2012, 2, 83-97.	0.8	73
173	Molecular mechanisms of cryptococcal meningitis. Virulence, 2012, 3, 173-181.	1.8	105
174	Chitin-Like Molecules Associate with Cryptococcus neoformans Glucuronoxylomannan To Form a Glycan Complex with Previously Unknown Properties. Eukaryotic Cell, 2012, 11, 1086-1094.	3.4	28

		CITATION REPORT	
#	Article	IF	Citations
175	Cryptococcosis. Clinics in Dermatology, 2012, 30, 599-609.	0.8	83
176	Identification of fungal diseases at necropsy. Pathology Research and Practice, 2012, 208, 549-552.	1.0	18

The role of dendritic cells in the innate recognition of pathogenic fungi ( $\langle i \rangle \langle i \rangle A$ . fumigatus $\langle i \rangle$ ,  $\langle i \rangle C$ .) Tj ETQq0 0 0.rgBT /Overlock 10 Tf

178	Antitumor, antibiotic and antileishmanial properties of the Pyranonaphthoquinone Psychorubrin from Mitracarpus frigidus. Anais Da Academia Brasileira De Ciencias, 2012, 84, 1081-1090.	0.3	29
179	An Overview on Cryptococcal Meningitis. , 0, , .		0
180	The Mycoses. , 2012, , 531-544.		0
182	Ten Challenges on Cryptococcus and Cryptococcosis. Mycopathologia, 2012, 173, 303-310.	1.3	55
183	Clinical, Epidemiological and Outcome Features of Patients with Cryptococcosis in Uberaba, Minas Gerais, Brazil. Mycopathologia, 2012, 173, 321-327.	1.3	33
184	Involvement of PDK1, PKC and TOR signalling pathways in basal fluconazole tolerance in <i>Cryptococcus neoformans</i> . Molecular Microbiology, 2012, 84, 130-146.	1.2	38
185	Induction of Cryptococcus laurentii α-galactosidase. Chemical Papers, 2012, 66, .	1.0	0
186	<i>Cryptococcus neoformans</i> phospholipase B1 activates host cell Rac1 for traversal across the blood-brain barrier. Cellular Microbiology, 2012, 14, 1544-1553.	1.1	62
187	Cryptococcosis in an immunocompetent pregnant woman. Revue Neurologique, 2013, 169, 92-93.	0.6	3
188	Rapid Antigen Tests. , 2013, , 31-51.		0
189	Elucidating the immunological function of the <i>Cryptococcus neoformans</i> capsule. Future Microbiology, 2013, 8, 1107-1116.	1.0	76
190	Pulmonary cryptococcosis presenting as wandering multiple bilateral shadows and hilar and mediastinal lymph node enlargement in the lungs. Tropical Doctor, 2013, 43, 144-147.	0.2	0
191	The Spectrum and Aetiology of Mycotic Infections from a Tertiary Care Hospital from Western Part of India. Journal of Clinical and Diagnostic Research JCDR, 2013, 7, 2157-9.	0.8	3
192	Opportunistic yeast infections: candidiasis, cryptococcosis, trichosporonosis and geotrichosis. JDDG - Journal of the German Society of Dermatology, 2013, 11, 381-394.	0.4	42
193	The antimicrobial activity of lapachol and its thiosemicarbazone and semicarbazone derivatives. Memorias Do Instituto Oswaldo Cruz, 2013, 108, 342-351.	0.8	41

#	Article	IF	CITATIONS
194	Effect of Erica sp. Honey against Microorganisms of Clinical Importance: Study of the Factors Underlying this Biological Activity. Molecules, 2013, 18, 4233-4246.	1.7	23
195	Letter to the Editor. Canadian Journal of Infectious Diseases and Medical Microbiology, 2014, 25, 118-119.	0.7	0
196	Host Defense Against Cryptococcal Disease: Is There a Role for B Cells and Antibody-Mediated Immunity?. Current Fungal Infection Reports, 2014, 8, 287-295.	0.9	5
197	Simultaneous coinfection with Cryptococcus neoformans and Mycobacterium tuberculosis in an adult. QJM - Monthly Journal of the Association of Physicians, 2014, 107, 223-224.	0.2	8
198	Literature-Based Gene Curation and Proposed Genetic Nomenclature for Cryptococcus. Eukaryotic Cell, 2014, 13, 878-883.	3.4	18
199	The cryptic sexual strategies of human fungal pathogens. Nature Reviews Microbiology, 2014, 12, 239-251.	13.6	97
200	Miscellaneous Fungal Diseases. , 2014, , 433-448.e5.		1
201	Simple and rapid method for the detection of Filobasidiella neoformans in a probiotic dairy product by using loop-mediated isothermal amplification. International Journal of Food Microbiology, 2014, 178, 107-112.	2.1	2
202	Symptomatic relapse of HIV-associated cryptococcal meningitis: recurrent cryptococcal meningitis or <i>Cryptococcus</i> -related immune reconstitution inflammatory syndrome?. International Journal of STD and AIDS, 2014, 25, 369-372.	0.5	10
203	Cryptococcal meningitis presenting with bilateral complete ophthalmoplegia: a case report. BMC Research Notes, 2014, 7, 328.	0.6	18
204	Comparisons of presentations and outcomes of cryptococcal meningitis between patients with and without hepatitis B virus infection. International Journal of Infectious Diseases, 2014, 20, 31-36.	1.5	18
205	Defect of CARD9 Leads to Impaired Accumulation of Gamma Interferon-Producing Memory Phenotype T Cells in Lungs and Increased Susceptibility to Pulmonary Infection with Cryptococcus neoformans. Infection and Immunity, 2014, 82, 1606-1615.	1.0	60
208	Cryptococcal Osteomyelitis in an Adolescent Survivor of T-Cell Acute Lymphoblastic Leukemia. Pediatric Infectious Disease Journal, 2015, 34, 662-666.	1.1	7
209	A new culture medium for recovering the agents of Cryptococcosis from environmental sources. Brazilian Journal of Microbiology, 2015, 46, 355-358.	0.8	11
210	Protein Composition of Infectious Spores Reveals Novel Sexual Development and Germination Factors in Cryptococcus. PLoS Genetics, 2015, 11, e1005490.	1.5	25
211	Cryptococcus neoformans Infection in Mice Lacking Type I Interferon Signaling Leads to Increased Fungal Clearance and IL-4-Dependent Mucin Production in the Lungs. PLoS ONE, 2015, 10, e0138291.	1.1	25
212	Cryptococcosis (Cryptococcus neoformans and Cryptococcus gattii). , 2015, , 2934-2948.e5.		16
213	Cluster ofCryptococcus neoformansInfections in Intensive Care Unit, Arkansas, USA, 2013. Emerging Infectious Diseases, 2015, 21, 1719-24.	2.0	16

#	Article	IF	CITATIONS
215	Molecular diagnosis of cryptococcal meningitis in cerebrospinal fluid: comparison of primer sets for Cryptococcus neoformans and Cryptococcus gattii species complex. Brazilian Journal of Infectious Diseases, 2015, 19, 62-67.	0.3	14
216	Criptococosis diseminada con afectación cutánea en un paciente con sida. Piel, 2015, 30, 68-70.	0.0	0
217	Cryptococcosis in HIV-infected hospitalized patients in Germany: Evidence for routine antigen testing. Journal of Infection, 2015, 71, 110-116.	1.7	7
218	Combination Versus Monotherapy for the Treatment of HIV Associated Cryptococcal Meningitis. Journal of Clinical and Diagnostic Research JCDR, 2015, 9, OC14-6.	0.8	5
219	Characterization of Lipids and Proteins Associated to the Cell Wall of the Acapsular Mutant <i>Cryptococcus neoformans</i> Cap 67. Journal of Eukaryotic Microbiology, 2015, 62, 591-604.	0.8	5
220	Unraveling the Novel Structure and Biosynthetic Pathway of O-Linked Glycans in the Golgi Apparatus of the Human Pathogenic Yeast Cryptococcus neoformans. Journal of Biological Chemistry, 2015, 290, 1861-1873.	1.6	23
221	Cryptococcal meningitis in HIV-negative patients with systemic connective tissue diseases. Neurological Research, 2015, 37, 283-287.	0.6	12
222	Characterization of the virulence of <i>Cryptococcus neoformans</i> strains in an insect model. Virulence, 2015, 6, 809-813.	1.8	17
224	Dectin-2 Deficiency Promotes Th2 Response and Mucin Production in the Lungs after Pulmonary Infection with Cryptococcus neoformans. Infection and Immunity, 2015, 83, 671-681.	1.0	64
225	Comparison of Antigen Detection and Nested PCR in CSF Samples of HIV Positive and Negative Patients with Suspected Cryptococcal Meningitis in a Tertiary Care Hospital. Journal of Clinical and Diagnostic Research JCDR, 2016, 10, DC12-5.	0.8	2
226	Distribution of theO-acetyl groups and β-galactofuranose units in galactoxylomannans of the opportunistic fungusCryptococcus neoformans. Glycobiology, 2016, 27, 582-592.	1.3	12
227	Cryptococcal meningitis initially presenting with eye symptoms in an immunocompetent patient: A case report. Experimental and Therapeutic Medicine, 2016, 12, 1119-1124.	0.8	6
228	Important Mycoses in Children in South America. Current Fungal Infection Reports, 2016, 10, 10-23.	0.9	0
229	Bioactivity-guided isolation of laevicarpin, an antitrypanosomal and anticryptococcal lactam from Piper laevicarpu (Piperaceae). Fìtoterapìâ, 2016, 111, 24-28.	1.1	15
230	Cryptococcosis in Acquired Immunodeficiency Syndrome Patients Clinically Confirmed and/or Diagnosed at Necropsy in a Teaching Hospital in Brazil. American Journal of Tropical Medicine and Hygiene, 2016, 95, 781-785.	0.6	12
231	Isolated cryptococcuria in a patient with impaired immunity. HIV and AIDS Review, 2016, 15, 94-96.	0.1	1
232	Cryptococcosis. Infectious Disease Clinics of North America, 2016, 30, 179-206.	1.9	473
233	Cryptococcemia in primary HIV infection. International Journal of STD and AIDS, 2016, 27, 1231-1233.	0.5	2

		15	0
#	ARTICLE	IF	CITATIONS
234	Repression of Proteases and Hsp90 Chaperone Expression Induced by an Antiretroviral in Virulent Environmental Strains of Cryptococcus neoformans. Microbial Ecology, 2017, 73, 583-589.	1.4	2
235	Cryptococcus and Cryptococcosis. , 2017, , 169-214.		2
236	Cryptococcal Lung Infections. Clinics in Chest Medicine, 2017, 38, 451-464.	0.8	30
237	Cysteinyl leukotrienes as novel host factors facilitating <i>Cryptococcus neoformans</i> penetration into the brain. Cellular Microbiology, 2017, 19, e12661.	1.1	14
238	Equine Pulmonary Cryptococcosis: A Comparative Literature Review and Evaluation of Fluconazole Monotherapy. Mycopathologia, 2017, 182, 413-423.	1.3	13
239	Molecular identification, antifungal resistance and virulence of <i>Cryptococcus neoformans</i> and <i>Cryptococcus deneoformans</i> isolated in Seville, Spain. Mycoses, 2017, 60, 40-50.	1.8	40
240	The epidemiology of cryptococcosis and the characterization of Cryptococcus neoformans isolated in a Brazilian University Hospital. Revista Do Instituto De Medicina Tropical De Sao Paulo, 2017, 59, e13.	0.5	36
241	Modulation of Replicative Lifespan in Cryptococcus neoformans: Implications for Virulence. Frontiers in Microbiology, 2017, 8, 98.	1.5	19
243	Relationship between intracranial pressure and antifungal agents levels in the CSF of patients with cryptococcal meningitis. Medical Mycology, 2018, 56, 257-262.	0.3	8
244	<i>In Vitro</i> and <i>In Vivo</i> Assessment of FK506 Analogs as Novel Antifungal Drug Candidates. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	44
245	Cryptococcal Meningitis: A Retrospective Cohort of a Brazilian Reference Hospital in the Post-HAART Era of Universal Access. Canadian Journal of Infectious Diseases and Medical Microbiology, 2018, 2018, 1-5.	0.7	12
246	Impact of Yeast Pigmentation on Heat Capture and Latitudinal Distribution. Current Biology, 2018, 28, 2657-2664.e3.	1.8	63
247	Biosynthesized silver and gold nanoparticles are potent antimycotics against opportunistic pathogenic yeasts and dermatophytes. International Journal of Nanomedicine, 2018, Volume 13, 695-703.	3.3	78
248	Current trends to control fungal pathogens: exploiting our knowledge in the host–pathogen interaction. Infection and Drug Resistance, 2018, Volume 11, 903-913.	1.1	21
249	Differences in Sirtuin Regulation in Response to Calorie Restriction in Cryptococcus neoformans. Journal of Fungi (Basel, Switzerland), 2018, 4, 26.	1.5	6
251	Infectious particle identity determines dissemination and disease outcome for the inhaled human fungal pathogen Cryptococcus. PLoS Pathogens, 2019, 15, e1007777.	2.1	48
252	First case report of fulminant septic shock from meningococcemia associated with Cryptococcus neoformans coinfection in an immunocompetent patient. Medical Mycology Case Reports, 2019, 26, 44-46.	0.7	2
253	Amino acid permeases in Cryptococcus neoformans are required for high temperature growth and virulence; and are regulated by Ras signaling. PLoS ONE, 2019, 14, e0211393.	1.1	12

#	Article	IF	CITATIONS
254	Characterization of the 6-O-acetylated lipoglucuronomannogalactan a novel Cryptococcus neoformans cell wall polysaccharide. Carbohydrate Research, 2019, 475, 1-10.	1.1	5
255	Life Cycle of <i>Cryptococcus neoformans</i> . Annual Review of Microbiology, 2019, 73, 17-42.	2.9	92
256	Catheter-related infection due to Papiliotrema laurentii in an oncologic patient: Case report and systematic review. Brazilian Journal of Infectious Diseases, 2019, 23, 451-461.	0.3	7
257	Rheological properties of cryptococcal polysaccharide change with fiber size, antibody binding and temperature. Future Microbiology, 2019, 14, 867-884.	1.0	14
258	Spore Cermination as a Target for Antifungal Therapeutics. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	21
259	T11TS immunotherapy augments microglial and lymphocyte protective immune responses against <i>Cryptococcus neoformans</i> in the brain. Scandinavian Journal of Immunology, 2019, 89, e12733.	1.3	6
260	Cryptococcus neoformans infection in Human Immunodeficiency Virus (HIV)-infected and HIV-uninfected patients at an inner-city tertiary care hospital in the Bronx. Medical Mycology, 2020, 58, 434-443.	0.3	11
261	Cryptococcal antigenemia prevalence and clinical data in HIVâ€infected patients from the reference centre at INIâ€FIOCRUZ, Rio de Janeiro, Southeast of Brazil. Mycoses, 2020, 63, 145-150.	1.8	4
262	Neuro-meningeal cryptococcal infection revealing a multiple myeloma. Pan African Medical Journal, 2020, 36, 324.	0.3	3
263	Nano nickel [1,2,4]â€ŧriazoleâ€3â€ŧhiones complex: Design, sonochemical synthesis, and antimicrobial evaluation. Journal of Heterocyclic Chemistry, 2020, 57, 3428-3441.	1.4	7
264	Limited Role of Mincle in the Host Defense against Infection with Cryptococcus deneoformans. Infection and Immunity, 2020, 88, .	1.0	8
265	Human IgM Inhibits the Formation of Titan-Like Cells in Cryptococcus neoformans. Infection and Immunity, 2020, 88, .	1.0	16
266	Cutaneous cryptococcosis: an underlying immunosuppression? Clinical manifestations, pathogenesis, diagnostic examinations and treatment. Postepy Dermatologii I Alergologii, 2020, 37, 154-158.	0.4	9
267	Production of IL-17A at Innate Immune Phase Leads to Decreased Th1 Immune Response and Attenuated Host Defense against Infection with <i>Cryptococcus deneoformans</i> . Journal of Immunology, 2020, 205, 686-698.	0.4	13
268	Odoriferous Therapy: A Review Identifying Essential Oils against Pathogens of the Respiratory Tract. Chemistry and Biodiversity, 2020, 17, e2000062.	1.0	23
269	Pulmonary Macrophage and Dendritic Cell Responses to Cryptococcus neoformans. Frontiers in Cellular and Infection Microbiology, 2020, 10, 37.	1.8	31
270	Cryptococcal Immune Reconstitution Inflammatory Syndrome: a Paradoxical Response to a Complex Organism. Current Treatment Options in Infectious Diseases, 2020, 12, 13-29.	0.8	0
271	Clinical impact of advanced chronic kidney disease in patients with non-HIV pulmonary cryptococcosis. BMC Pulmonary Medicine, 2020, 20, 116.	0.8	2

#	Article	IF	CITATIONS
272	Pleiotropy and epistasis within and between signaling pathways defines the genetic architecture of fungal virulence. PLoS Genetics, 2021, 17, e1009313.	1.5	14
273	AIDS-Related Mycoses. , 2021, , 763-780.		0
274	Round Granulomatous Lesions in a Young Girl: A Quiz. Acta Dermato-Venereologica, 2021, 101, adv00464.	0.6	0
275	Cryptococcus Infection in Captive Callitrichids in the United Kingdom. Journal of Comparative Pathology, 2021, 183, 1-8.	0.1	2
276	Dexamethasone and Methylprednisolone Promote Cell Proliferation, Capsule Enlargement, and in vivo Dissemination of C. neoformans. Frontiers in Fungal Biology, 2021, 2, .	0.9	2
277	Influence of Galectin-3 on the Innate Immune Response during Experimental Cryptococcosis. Journal of Fungi (Basel, Switzerland), 2021, 7, 492.	1.5	0
278	Cryptococosis menÃngea y el sistema inmune. A Propósito de un Caso. Revista Cuarzo, 2021, 27, 45-57.	0.1	0
279	Transcriptional Changes in Pulmonary Phagocyte Subsets Dictate the Outcome Following Interaction With The Fungal Pathogen Cryptococcus neoformans. Frontiers in Immunology, 2021, 12, 722500.	2.2	5
280	The role of Toll-like receptor 9 in a murine model of Cryptococcus gattii infection. Scientific Reports, 2021, 11, 1407.	1.6	10
281	Cryptococcus in Wildlife and Free-Living Mammals. Journal of Fungi (Basel, Switzerland), 2021, 7, 29.	1.5	22
283	Drug Resistance in Cryptococcus neoformans. , 2009, , 967-985.		4
284	Drug Resistance in Cryptococcosis. , 2017, , 1119-1140.		4
286	DNA-Based Detection of Human Pathogenic Fungi: Dermatophytes, Opportunists, and Causative Agents of Deep Mycoses. , 2010, , 357-415.		6
287	Cryptococcus Neoformans Meningitis Cases Among China's HIV-Infected Population may have been Severely Under-Reported. Mycopathologia, 2020, 185, 971-974.	1.3	10
288	Cryptococcus neoformans. , 2010, , 3287-3303.		11
289	Miscellaneous Fungal Diseases. , 2007, , 431-445.		4
290	Bacterial and Miscellaneous Infections of the Liver. , 2006, , 747-765.		5
291	Cryptococcus neoformans. , 2011, , 1056-1058.e1.		1

	Сіта	TION REPORT	
#	Article	IF	CITATIONS
292	Molecular identification, genotypic heterogeneity and comparative pathogenicity of environmental isolates of Papiliotrema laurentii. Journal of Medical Microbiology, 2020, 69, 1285-1292.	0.7	3
293	Fatal cryptococcal meningitis in a HIVâ€seronegative patient with liver cirrhosis. JMM Case Reports, 2014, 1, .	1.3	2
295	Cryptococcus neoformans : a Sugar-Coated Killer. , 0, , 279-303.		6
296	Systematics of the Genus Cryptococcus and Its Type Species C. neoformans. , 0, , 1-15.		12
297	Vaccines and Antibody Therapies from Cryptococcus neoformans to Melanoma. , 0, , 537-546.		1
298	FTY720 reactivates cryptococcal granulomas in mice through S1P receptor 3 on macrophages. Journal of Clinical Investigation, 2020, 130, 4546-4560.	3.9	24
299	Characterization of the PMT Gene Family in Cryptococcus neoformans. PLoS ONE, 2009, 4, e6321.	1.1	42
300	Direct Inhibition of T-Cell Responses by the Cryptococcus Capsular Polysaccharide Glucuronoxylomannan. PLoS Pathogens, 2006, 2, e120.	2.1	102
302	Antifungal activity of the naphthoquinone beta-lapachone against disseminated infection with Cryptococcus neoformans var. neoformans in dexamethasone-immunosuppressed Swiss mice. Brazilian Journal of Medical and Biological Research, 2010, 43, 345-349.	0.7	30
303	Cryptococcal meningitis in Rio de Janeiro State, Brazil, 1994-2004. Cadernos De Saude Publica, 2008, 24 2582-2592.	4, 0.4	19
304	Chronic Obstructive Pulmonary Disease (COPD) and Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome (ACOS) are Risk Factors for Cryptococcosis. The Open Allergy Journal, 2020, 11, 1-4.	0.5	3
305	CRYPTOCOCCAL MENINGITIS AND PULMONARY CRYPTOCOCCOSIS IN A NON-HIV INFECTED PATIENT. Electronic Journal of General Medicine, 2006, 3, 80-82.	0.3	5
306	Diagnosis of Cryptococcosis. Infectious Disease and Therapy, 2007, , 239-266.	0.0	1
307	Epidemiology of invasive fungal infections in the mediterranean area. Mediterranean Journal of Hematology and Infectious Diseases, 2011, 3, e20110016.	0.5	16
308	Disseminated Cryptococcosis in a Patient With Nephrotic Syndrome. Archives of Pediatric Infectious Diseases, 2014, 3, .	0.1	1
309	Deficiency of lung-specific claudin-18 leads to aggravated infection with Cryptococcus deneoformans through dysregulation of the microenvironment in lungs. Scientific Reports, 2021, 11, 21110.	1.6	8
310	Gender-Specific Issues in Fungal Infections. , 2004, , 910-922.		1
311	The Mycoses. , 2006, , 530-542.		0

#	Article	IF	CITATIONS
312	Infektionserkrankungen. , 2007, , 439-533.		1
313	Prostatitis in the Immunocompromised Patient. , 2008, , 45-58.		0
316	A RAPIDLY GROWING LESION OF PULMONARY CRYPTOCOCCOSIS MIMICKING A METASTATIC LUNG TUMOR. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association), 2008, 69, 2827-2831.	0.0	1
318	Fungal and Protozoal Diseases. , 2009, , 213-239.		1
319	Epidemiology of Fungal Infections. , 2009, , 11-48.		0
321	T Cell and Dendritic Cell Immune Responses to Cryptococcus. , 0, , 387-396.		5
322	Mycotic Agents of Human Disease. , 0, , 163-178.		0
323	Opportunisitic Pathogens of Humans. Advances in Environmental Microbiology, 2016, , 301-357.	0.1	0
324	Mycotic Agents. , 0, , 147-162.		0
325	Infections of the Nervous System. , 2018, , 507-541.		0
326	Cryptococcal Meningitis. , 2018, , 57-77.		1
328	Sequential infection of Epsteinâ€Barr virus and cryptococcal encephalitis after umbilical cord blood transplantation in a child with Xâ€linked adrenoleukodystrophy. Pediatric Transplantation, 2021, 25, e13956.	0.5	0
330	Rapid Antigen Tests. , 2006, , 23-41.		1
331	25 Mycoses and algal infections. , 2010, , 489-513.		0
332	Cholesterol and sphingomyelin are critical for Fcγ receptor–mediated phagocytosis of Cryptococcus neoformans by macrophages. Journal of Biological Chemistry, 2021, 297, 101411.	1.6	12
333	Cryptococcosis Presenting as Cerebrovascular Disease. Cureus, 2021, 13, e19442.	0.2	3
334	Role of IL-17 in Morphogenesis and Dissemination of Cryptococcus neoformans during Murine Infection. Microorganisms, 2022, 10, 373.	1.6	1
335	Deciphering the Association among Pathogenicity, Production and Polymorphisms of Capsule/Melanin in Clinical Isolates of Cryptococcus neoformans var. grubii VNI. Journal of Fungi (Basel, Switzerland), 2022, 8, 245.	1.5	3

#	Article	IF	CITATIONS
336	Pathology of selected infectious diseases. , 0, , 85-183.		0
337	Infectious disease complications in leukemia. , 2006, , 805-828.		0
339	Pulmonary Fibrosis and Hypereosinophilia in TLR9-/- Mice Infected by Cryptococcus gattii. Pathogens, 2022, 11, 987.	1.2	2
340	Bilateral simultaneous lower motor nerve facial palsy as presenting symptom of cryptococcal meningitis in a non-immunocompromised patient. Journal of Neurosciences in Rural Practice, 0, .	0.3	0
341	Disseminated Cryptococcal Infection in Kidney Transplant Recipients. , 2022, , 199-204.		0
342	PAMPs and Host Immune Response in Cryptococcal Infection. Medical Mycology Journal, 2022, 63, 133-138.	0.5	1
343	Fun with fungi: a comprehensive review of common fungal organisms encountered in cytology. Journal of the American Society of Cytopathology, 2023, 12, 153-169.	0.2	5
344	Extension of <i>O</i> -Linked Mannosylation in the Golgi Apparatus Is Critical for Cell Wall Integrity Signaling and Interaction with Host Cells in Cryptococcus neoformans Pathogenesis. MBio, 2022, 13, .	1.8	3
345	Adjuvant Pam3CSk4 does not improve the immunization against <i>Cryptococcus gattii</i> infection in C57BL/6 mice. PeerJ, 0, 11, e14778.	0.9	0
347	Lack of Association between YEASTONE Antifungal Susceptibility Tests and Clinical Outcomes of Cryptococcus Meningitis. Journal of Fungi (Basel, Switzerland), 2023, 9, 232.	1.5	2
348	Importance of Clinical Isolates in Cryptococcus neoformans Research. Journal of Fungi (Basel,) Tj ETQq0 0 0 rgBT	Qverlock	10 Tf 50 342

0

351	Mouse Model of Latent Cryptococcal Infection and Reactivation. Methods in Molecular Biology, 2023, , 87-98.	0.4	0

Implications of phospholipase A2 in fungal diseases. , 2023, , 3-7.